FRUZAQLA

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Italy, Lithuania, Romania, Spain.

Active ingredients

The drug FRUZAQLA contains one active pharmaceutical ingredient (API):

1	Fruquintinib UNII 49DXG3M5ZW - FRUQUINTINIB
	Fruquintinib is a selective tyrosine kinase inhibitor of VEGFR-1, -2, and -3 with antitumor effects resulting from suppression of tumour angiogenesis.
	Read more about Fruquintinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FRUZAQLA Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)
FRUZAQLA Hard capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EK04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3081406, 3081417
ES	Centro de información online de medicamentos de la AEMPS	1241827001, 1241827002
FR	Base de données publique des médicaments	63200612, 64771069
IT	Agenzia del Farmaco	051360016
LT	Valstybinė vaistų kontrolės tarnyba	1100271, 1100272
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70451001, W70452001
US	FDA, National Drug Code	63020-210, 63020-225